Giovanni Fabbrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1251820/publications.pdf

Version: 2024-02-01

116194 145109 4,233 111 36 60 citations h-index g-index papers 113 113 113 4663 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Driving motor cortex oscillations modulates bradykinesia in Parkinson's disease. Brain, 2022, 145, 224-236.	3.7	57
2	Longitudinal evaluation of patients with isolated head tremor. Parkinsonism and Related Disorders, 2022, 94, 10-12.	1.1	10
3	The role of frailty in Parkinson's disease: a cross-sectional study. Journal of Neurology, 2022, 269, 3006-3014.	1.8	7
4	The Effectiveness of Equine Therapy Intervention on Activities of Daily Living, Quality of Life, Mood, Balance and Gait in Individuals with Parkinson's Disease. Healthcare (Switzerland), 2022, 10, 561.	1.0	5
5	Evaluation of the Psychometric Properties of Jebsen Taylor Hand Function Test (JTHFT) in Italian Individuals With Multiple Sclerosis. Frontiers in Neurology, 2022, 13, 847807.	1.1	1
6	Neurofilament assessment in patients with cervical dystonia. Parkinsonism and Related Disorders, 2022, 98, 70-71.	1.1	4
7	The Role of the Motor Cortex in Tremor Suppression in Parkinson's Disease. Journal of Parkinson's Disease, 2022, , 1-7.	1.5	3
8	Tools to assess the quality of life in patients with Parkinson's disease: a systematic review. Expert Review of Pharmacoeconomics and Outcomes Research, 2021, 21, 55-68.	0.7	30
9	Neuroimaging in idiopathic adult-onset focal dystonia. Neurological Sciences, 2021, 42, 2947-2950.	0.9	3
10	Evaluation of the Psychometric Properties of the Scale A-ONE: An Italian Cross-Sectional Study. Occupational Therapy International, 2021, 2021, 1-6.	0.3	0
11	Genetic variants in levodopa-induced dyskinesia (LID): A systematic review and meta-analysis. Parkinsonism and Related Disorders, 2021, 84, 52-60.	1.1	13
12	Attention-Demanding Cognitive Tasks Worsen Postural Control in Patients With Cervical Dystonia: A Case-Control Study. Frontiers in Neurology, 2021, 12, 666438.	1.1	7
13	Response to "Response to isolated head tremor: A DAT-SPECT and somatosensory temporal discrimination study― Parkinsonism and Related Disorders, 2021, 87, 168-169.	1.1	O
14	The importance of suicide risk assessment in patients affected by neurofibromatosis. International Journal of Psychiatry in Clinical Practice, 2021, 25, 350-355.	1.2	3
15	Sudden Onset, Fixed Dystonia and Acute Peripheral Trauma as Diagnostic Clues for Functional Dystonia. Movement Disorders Clinical Practice, 2021, 8, 1107-1111.	0.8	5
16	Effect of Botulinum Toxin on Non-Motor Symptoms in Cervical Dystonia. Toxins, 2021, 13, 647.	1.5	13
17	Effectiveness of SaeboReJoyce in the Evaluation of the Improvement of the Occupational Performance in Parkinson's Disease: An Outcome Research. Advances in Intelligent Systems and Computing, 2020, , 63-70.	0.5	1
18	Modifiable risk and protective factors in disease development, progression and clinical subtypes of Parkinson's disease: What do prospective studies suggest?. Neurobiology of Disease, 2020, 134, 104671.	2.1	48

#	Article	IF	CITATIONS
19	Validation and Cross-Cultural Adaptation of the Volitional Questionnaire in an Italian Population with Psychiatric Disorders: A Cross-Sectional Study. Occupational Therapy in Health Care, 2020, 34, 19-31.	0.2	4
20	<scp><i>GBA</i>â€Related</scp> Parkinson's Disease: Dissection of Genotype–Phenotype Correlates in a Large Italian Cohort. Movement Disorders, 2020, 35, 2106-2111.	2.2	83
21	Suicidal ideation, hopelessness, and affective temperament in patients with blepharospasm. International Journal of Psychiatry in Clinical Practice, 2020, 25, 1-6.	1.2	5
22	Efficacy of Occupational Therapy Interventions on Quality of Life in Patients with Parkinson's Disease: A Systematic Review and Metaâ€Analysis. Movement Disorders Clinical Practice, 2020, 7, 891-901.	0.8	12
23	Risk factors of Parkinson disease. Neurology, 2020, 95, e2500-e2508.	1.5	41
24	<p>Impact of Supporting People with Advanced Parkinson's Disease on Carer's Quality of Life and Burden</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16, 2899-2912.	1.0	9
25	Isolated head tremor: A DAT-SPECT and somatosensory temporal discrimination study. Parkinsonism and Related Disorders, 2020, 81, 56-59.	1.1	8
26	Enhancing Gamma Oscillations Restores Primary Motor Cortex Plasticity in Parkinson's Disease. Journal of Neuroscience, 2020, 40, 4788-4796.	1.7	51
27	Psychiatric disorders in blepharospasm: A 10-year follow-up study. Psychiatry Research, 2020, 290, 113092.	1.7	0
28	The TANDEM investigation: efficacy and tolerability of levodopa-carbidopa intestinal gel in (LCIG) advanced Parkinson's disease patients. Journal of Neural Transmission, 2020, 127, 881-891.	1.4	8
29	Does acute peripheral trauma contribute to idiopathic adult-onset dystonia?. Parkinsonism and Related Disorders, 2020, 71, 40-43.	1.1	18
30	Validity and reliability of the 12-item Berg Balance Scale in an Italian population with Parkinson's disease: A cross sectional study. Arquivos De Neuro-Psiquiatria, 2020, 78, 419-423.	0.3	4
31	Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications. Journal of Neurology, 2019, 266, 2780-2785.	1.8	25
32	Progressive supranuclear palsy, multiple system atrophy and corticobasal degeneration. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2019, 165, 155-177.	1.0	16
33	The role of sensory information in the pathophysiology of focal dystonias. Nature Reviews Neurology, 2019, 15, 224-233.	4.9	66
34	Treatment of psychiatric disturbances in hypokinetic movement disorders. Expert Review of Neurotherapeutics, 2019, 19, 965-981.	1.4	8
35	Abnormal cortical facilitation and L-dopa-induced dyskinesia in Parkinson's disease. Brain Stimulation, 2019, 12, 1517-1525.	0.7	53
36	The clinical correlates of suicidal ideation in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 63, 54-59.	1,1	18

#	Article	IF	CITATIONS
37	Writing, reading, and speaking in blepharospasm. Journal of Neurology, 2019, 266, 1136-1140.	1.8	6
38	Parkinson's disease among migrants in Europe: estimating the magnitude of an emerging phenomenon. Journal of Neurology, 2019, 266, 1120-1126.	1.8	4
39	Validation of the short version of the Van Lieshout Test in an Italian population with cervical spinal cord injuries: a cross-sectional study. Spinal Cord, 2019, 57, 339-345.	0.9	30
40	Suicidal ideation, perceived disability, hopelessness and affective temperaments in patients affected by Parkinson's disease. International Journal of Clinical Practice, 2019, 73, e13287.	0.8	13
41	Treatment of psychiatric disturbances in common hyperkinetic movement disorders. Expert Review of Neurotherapeutics, 2019, 19, 55-65.	1.4	7
42	Expert recommendations for diagnosing cervical, oromandibular, and limb dystonia. Neurological Sciences, 2019, 40, 89-95.	0.9	44
43	Suicide in Parkinson's Disease: A Systematic Review. CNS and Neurological Disorders - Drug Targets, 2019, 18, 466-477.	0.8	15
44	Neuropsychiatric disturbances in atypical parkinsonian disorders. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 2643-2656.	1.0	21
45	Cognitive behavioral group therapy versus psychoeducational intervention in Parkinson's disease. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 399-405.	1.0	21
46	Reliability and Validity of the Geriatric Depression Scale in Italian Subjects with Parkinson's Disease. Parkinson's Disease, 2018, 2018, 1-6.	0.6	30
47	Language use at Italian medical congresses. Neurological Sciences, 2018, 39, 1779-1780.	0.9	0
48	Somatosensory temporal discrimination in Parkinson's disease, dystonia and essential tremor: Pathophysiological and clinical implications. Clinical Neurophysiology, 2018, 129, 1849-1853.	0.7	23
49	Quality of life in Parkinson's disease: Italian validation of the Parkinson's Disease Questionnaire (PDQ-39-IT). Neurological Sciences, 2018, 39, 1903-1909.	0.9	32
50	Which patients discontinue? Issues on Levodopa/carbidopa intestinal gel treatment: Italian multicentre survey of 905 patients with long-term follow-up. Parkinsonism and Related Disorders, 2017, 38, 90-92.	1.1	44
51	A Web Resource for Levodopa-Induced Dyskinesia Genetics in Parkinson's Disease. Neuroinformatics, 2017, 15, 297-300.	1.5	2
52	Increased Blinking May Be a Precursor of Blepharospasm: A Longitudinal Study. Movement Disorders Clinical Practice, 2017, 4, 733-736.	0.8	33
53	Functional disconnection of thalamic and cerebellar dentate nucleus networks in progressive supranuclear palsy and corticobasal syndrome. Parkinsonism and Related Disorders, 2017, 39, 52-57.	1.1	25
54	Re-emergent tremor in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 36, 41-46.	1.1	38

#	Article	IF	CITATIONS
55	Interoceptive sensitivity in patients with cervical dystonia. Parkinsonism and Related Disorders, 2017, 44, 129-132.	1.1	4
56	Genetic Paradoxes in an Italian Family with <i><scp>PARK</scp>2</i> Multiexon Duplication. Movement Disorders Clinical Practice, 2017, 4, 889-892.	0.8	1
57	Neurophysiological studies on atypical parkinsonian syndromes. Parkinsonism and Related Disorders, 2017, 42, 12-21.	1.1	25
58	The effect of L-dopa in Parkinson's disease as revealed by neurophysiological studies of motor and sensory functions. Expert Review of Neurotherapeutics, 2017, 17, 181-192.	1.4	29
59	Abnormal Temporal Coupling of Tactile Perception and Motor Action in Parkinson's Disease. Frontiers in Neurology, 2017, 8, 249.	1.1	23
60	Does the Somatosensory Temporal Discrimination Threshold Change over Time in Focal Dystonia?. Neural Plasticity, 2017, 2017, 1-6.	1.0	12
61	Factors influencing psychological well-being in patients with Parkinson's disease. PLoS ONE, 2017, 12, e0189682.	1.1	32
62	Altered Kinematics of Facial Emotion Expression and Emotion Recognition Deficits Are Unrelated in Parkinson's Disease. Frontiers in Neurology, 2016, 7, 230.	1.1	33
63	Abnormal Salivary Total and Oligomeric Alpha-Synuclein in Parkinson's Disease. PLoS ONE, 2016, 11, e0151156.	1.1	100
64	<i>PRKRA</i> Mutation Causing Earlyâ€Onset Generalized Dystoniaâ€Parkinsonism (DYT16) in an Italian Family. Movement Disorders, 2016, 31, 765-767.	2.2	29
65	Somatosensory temporal discrimination threshold in Parkinson's disease parallels disease severity and duration. Clinical Neurophysiology, 2016, 127, 2985-2989.	0.7	35
66	Parkinson's disease: Autoimmunity and neuroinflammation. Autoimmunity Reviews, 2016, 15, 1005-1011.	2.5	275
67	Bradykinesia in early and advanced Parkinson's disease. Journal of the Neurological Sciences, 2016, 369, 286-291.	0.3	63
68	Non-motor symptoms in patients with adult-onset focal dystonia: Sensory and psychiatric disturbances. Parkinsonism and Related Disorders, 2016, 22, S111-S114.	1.1	89
69	Cognitive Behavioral Therapy in Movement Disorders: A Review. Movement Disorders Clinical Practice, 2015, 2, 107-115.	0.8	79
70	Spread of Muscle Spasms in Hemifacial Spasm. Movement Disorders Clinical Practice, 2015, 2, 53-55.	0.8	7
71	Somatosensory temporal discrimination in essential tremor and isolated head and voice tremors. Movement Disorders, 2015, 30, 822-827.	2.2	27
72	Development and validation of a clinical scale for rating the severity of Blepharospasm. Movement Disorders, 2015, 30, 525-530.	2.2	60

#	Article	IF	Citations
73	Clinical variables associated with treatment changes in Parkinson's disease: results from the longitudinal phase of the REASON study. Neurological Sciences, 2015, 36, 935-943.	0.9	6
74	Is tremor in dystonia a phenotypic feature of dystonia?. Neurology, 2015, 84, 1053-1059.	1.5	98
75	CBT Group Intervention for Depression, Anxiety, and Motor Symptoms in Parkinson's Disease: Preliminary Findings. International Journal of Cognitive Therapy, 2015, 8, 11-20.	1.3	6
76	Clinical course of psychiatric disorders in patients with cervical dystonia. Psychiatry Research, 2015, 229, 583-585.	1.7	45
77	Botulinum toxin and blink rate in patients with blepharospasm and increased blinking. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 336-340.	0.9	16
78	Parkinsonian Patients and Poor Awareness of Dyskinesias. Frontiers in Neurology, 2014, 5, 32.	1.1	21
79	Dyskinesias and motor symptoms onset in Parkinson disease. Parkinsonism and Related Disorders, 2014, 20, 1427-1429.	1.1	7
80	Bradykinesia of posed smiling and voluntary movement of the lower face in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, 370-375.	1.1	33
81	Psychiatric disturbances in patients with progressive supranuclear palsy: A case-control study. Parkinsonism and Related Disorders, 2014, 20, 965-968.	1.1	23
82	Validation of the Italian version of the Movement Disorder Society—Unified Parkinson's Disease Rating Scale. Neurological Sciences, 2013, 34, 683-687.	0.9	123
83	Reasons driving treatment modification in Parkinson's disease: Results from the cross-sectional phase of the REASON study. Parkinsonism and Related Disorders, 2013, 19, 1130-1135.	1.1	16
84	Poor self-awareness of levodopa-induced dyskinesias in Parkinson's disease: Clinical features and mechanisms. Parkinsonism and Related Disorders, 2013, 19, 1004-1008.	1.1	61
85	Abnormal experimentally- and behaviorally-induced LTP-like plasticity in focal hand dystonia. Experimental Neurology, 2013, 240, 64-74.	2.0	47
86	Facial bradykinesia. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 681-685.	0.9	117
87	Is increased blinking a form of blepharospasm?. Neurology, 2013, 80, 2236-2241.	1.5	44
88	Selegiline. Clinical Neuropharmacology, 2012, 35, 134-140.	0.2	34
89	Abnormal Cortical Synaptic Plasticity in Primary Motor Area in Progressive Supranuclear Palsy. Cerebral Cortex, 2012, 22, 693-700.	1.6	49
90	Age at onset and symptom spread in primary adultâ€onset blepharospasm and cervical dystonia. Movement Disorders, 2012, 27, 1447-1450.	2.2	46

#	Article	IF	Citations
91	A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson's disease. Expert Opinion on Pharmacotherapy, 2012, 13, 2269-2280.	0.9	25
92	Psychiatric disorders in patients with essential tremor. Parkinsonism and Related Disorders, 2012, 18, 971-973.	1.1	29
93	Effects of subthalamic nucleus deep brain stimulation and l-dopa on blinking in Parkinson's disease. Experimental Neurology, 2012, 235, 265-272.	2.0	49
94	Somatosensory temporal discrimination tested in patients receiving botulinum toxin injection for cervical dystonia. Movement Disorders, 2011, 26, 742-746.	2.2	40
95	Psychiatric disorders in adult onset focal dystonia. Movement Disorders, 2011, 26, 1572-1572.	2.2	4
96	Soluble and controlled-release preparations of levodopa: do we really need them?. Journal of Neurology, 2010, 257, 292-297.	1.8	5
97	Psychiatric disorders in adultâ€onset focal dystonia: A caseâ€control study. Movement Disorders, 2010, 25, 459-465.	2.2	156
98	Task force report on scales to assess dyskinesia in Parkinson's disease: Critique and recommendations. Movement Disorders, 2010, 25, 1131-1142.	2.2	90
99	Subthalamic nucleus stimulation and somatosensory temporal discrimination in Parkinson's disease. Brain, 2010, 133, 2656-2663.	3.7	80
100	Onset and spread of dyskinesias and motor symptoms in Parkinson's disease. Movement Disorders, 2009, 24, 2091-2096.	2.2	26
101	Cranial movement disorders: clinical features, pathophysiology, differential diagnosis and treatment. Nature Clinical Practice Neurology, 2009, 5, 93-105.	2.7	40
102	Voluntary, spontaneous, and reflex blinking in Parkinson's disease. Movement Disorders, 2008, 23, 669-675.	2.2	114
103	Psychopathological features of obsessive–compulsive disorder in an Italian family with Gilles de la Tourette syndrome not linked to the SLITRK1 gene. Psychiatry Research, 2008, 161, 109-111.	1.7	13
104	Voluntary, spontaneous and reflex blinking in patients with clinically probable progressive supranuclear palsy. Brain, 2008, 132, 502-510.	3.7	64
105	Levodopa-induced dyskinesias. Movement Disorders, 2007, 22, 1379-1389.	2.2	422
106	A large Italian family with Gilles de la Tourette syndrome: Clinical study and analysis of the <i>SLITRK1</i> gene. Movement Disorders, 2007, 22, 2229-2234.	2.2	31
107	A Comparative Study of Primary and Secondary Hemifacial Spasm. Archives of Neurology, 2006, 63, 441.	4.9	106
108	Drug Insight: new drugs in development for Parkinson's disease. Nature Clinical Practice Neurology, 2006, 2, 600-610.	2.7	14

#	Article	IF	CITATIONS
109	Relationship between eye symptoms and blepharospasm: A multicenter case–control study. Movement Disorders, 2005, 20, 1564-1570.	2.2	86
110	Excessive daytime sleepiness in de novo and treated Parkinson's disease. Movement Disorders, 2002, 17, 1026-1030.	2.2	90
111	Pramipexole in Parkinson's disease. A short-term study using the combined levodopa-dopamine agonist test. Functional Neurology, 2002, 17, 199-201.	1.3	1